ReElement Technologies stock soars after securing $1.4B government deal
Investing.com - Leerink Partners has raised its price target on HCA Healthcare Inc (NYSE:HCA) to $470.00 from $465.00 while maintaining an Outperform rating. The new target aligns with broader analyst sentiment, as InvestingPro data shows analyst targets ranging from $333 to $495, with the stock currently trading near its 52-week high at $447.04.
The research firm cited HCA’s third-quarter 2025 results, which demonstrated continued strong demand, improved surgical growth, higher core performance, and upside in the Directed Payment Programs (DPP). This performance contributes to HCA’s impressive 6.37% revenue growth and robust market position, with a market capitalization of $104.6 billion.
HCA Healthcare has revised its guidance to incorporate stronger core and DPP trends, though Leerink Partners noted that the DPP guidance still appears conservative and excludes several key states.
The hospital operator expects admission growth of 2-3% in 2026, and likely closer to 2% without subsidies, which Leerink characterized as "perhaps the most bullish statement on the call."
Leerink Partners also highlighted that revenue growth continues to outpace costs for HCA, demand remains solid, share buybacks are very active, and the earnings outlook based on consensus estimates remains attractive.
In other recent news, HCA Holdings Inc. reported impressive financial results for the third quarter of 2025, outperforming analysts’ expectations. The company achieved a diluted earnings per share (EPS) of $6.96, which was notably higher than the projected $5.72. This represents a 21.68% positive surprise in EPS. Additionally, HCA Holdings generated revenue of $19.16 billion, surpassing the anticipated $18.56 billion. These results highlight the company’s strong financial performance in the recent quarter.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.